

# Glen J Pearson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8751676/publications.pdf>

Version: 2024-02-01

77  
papers

3,825  
citations

331259

21  
h-index

138251

58  
g-index

82  
all docs

82  
docs citations

82  
times ranked

4664  
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2016, 32, 1263-1282.	0.8	775
2	2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology, 2013, 29, 151-167.	0.8	680
3	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult "2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	0.8	653
4	2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology, 2021, 37, 1129-1150.	0.8	367
5	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). Canadian Journal of Cardiology, 2016, 32, S35-S65.	0.8	194
6	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Canadian Journal of Cardiology, 2013, 29, 1553-1568.	0.8	153
7	Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Canadian Journal of Cardiology, 2018, 34, 1553-1563.	0.8	105
8	Evolution in the practice of pharmacy—not a revolution!. Cmaj, 2007, 176, 1295-1296.	0.9	79
9	Correlation of cardiovascular magnetic resonance imaging findings and endomyocardial biopsy results in patients undergoing screening for heart transplant rejection. Journal of Heart and Lung Transplantation, 2015, 34, 643-650.	0.3	77
10	A Systematic Review of the Evidence for Pharmacist Care of Patients With Dyslipidemia. Pharmacotherapy, 2012, 32, 222-233.	1.2	70
11	Use of OTC and Herbal Products in Patients with Cardiovascular Disease. Annals of Pharmacotherapy, 2003, 37, 899-904.	0.9	56
12	A randomized trial of a community-based approach to dyslipidemia management. Canadian Pharmacists Journal, 2016, 149, 283-292.	0.4	53
13	Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology, 2002, 89, 390-394.	0.7	40
14	Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update. Cmaj, 2018, 190, E1192-E1206.	0.9	39
15	Supratherapeutic Response to Ezetimibe Administered with Cyclosporine. Annals of Pharmacotherapy, 2005, 39, 1561-1565.	0.9	36
16	Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Canadian Family Physician, 2016, 62, 32-7.	0.1	36
17	Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial. Canadian Journal of Cardiology, 2018, 34, 1600-1605.	0.8	29
18	Long-Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Cardiovascular Events: Extended Follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Pharmacotherapy, 2005, 25, 110-115.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. <i>Canadian Journal of Cardiology</i> , 2014, 30, 377-380.	0.8	27
20	Cardiovascular MRI Predicts 5-Year Adverse Clinical Outcome in Heart Transplant Recipients. <i>American Journal of Transplantation</i> , 2014, 14, 2055-2061.	2.6	26
21	Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2003, 28, 329-338.	0.7	23
22	An Evaluation of Teaching Physical Examination to Pharmacists. <i>Canadian Pharmacists Journal</i> , 2012, 145, 174-179.e1.	0.4	22
23	Professional Use of Social Media by Pharmacists. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, 22-7.	0.1	21
24	Pretransplant Diabetes, Not Donor Age, Predicts Long-Term Outcomes in Cardiac Transplantation. <i>Journal of Cardiac Surgery</i> , 2006, 21, 117-124.	0.3	19
25	Prevention and management of statin adverse effects: A practical approach for pharmacists. <i>Canadian Pharmacists Journal</i> , 2018, 151, 179-188.	0.4	19
26	New advances in antirejection therapy. <i>Current Opinion in Cardiology</i> , 2007, 22, 117-122.	0.8	17
27	Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2001, 26, 351-361.	0.7	15
28	The Importance of In-Hospital Statin Therapy for Patients with Acute Coronary Syndromes. <i>Pharmacotherapy</i> , 2003, 23, 506-513.	1.2	14
29	Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review. <i>Transplantation Reviews</i> , 2009, 23, 171-177.	1.2	14
30	Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient. <i>Annals of Pharmacotherapy</i> , 2007, 41, 133-137.	0.9	13
31	Pharmacologic Treatment of Patients With Myocardial Ischemia With No Obstructive Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2018, 121, 888-895.	0.7	12
32	2016 Guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. <i>Canadian Pharmacists Journal</i> , 2017, 150, 243-250.	0.4	11
33	Colchicine for the Primary and Secondary Prevention of Pericarditis: An Update. <i>Annals of Pharmacotherapy</i> , 2009, 43, 2075-2081.	0.9	9
34	Evaluation of Preventive Cardiovascular Pharmacotherapy after Coronary Artery Bypass Graft Surgery. <i>Pharmacotherapy</i> , 2014, 34, 464-472.	1.2	9
35	Assessment of new onset postcoronary artery bypass surgery atrial fibrillation: current practice pattern review and the development of treatment guidelines. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2002, 27, 21-37.	0.7	8
36	The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. <i>Canadian Journal of Cardiology</i> , 2006, 22, 939-945.	0.8	8

#	ARTICLE	IF	CITATIONS
37	Frequency of Intensive Statin Therapy in Patients With Acute Coronary Syndrome Admitted to a Tertiary Care Center. <i>American Journal of Cardiology</i> , 2012, 109, 1-5.	0.7	8
38	Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease by Pharmacists. <i>Canadian Pharmacists Journal</i> , 2008, 141, S11-S16.	0.4	7
39	Adverse drug reactions. <i>Canadian Pharmacists Journal</i> , 2014, 147, 233-238.	0.4	7
40	Secondary Stroke Prevention: Practice Patterns in a Tertiary Care Stroke Service. <i>Canadian Journal of Neurological Sciences</i> , 2010, 37, 245-251.	0.3	6
41	Updated guidelines for the management of dyslipidemia and prevention of cardiovascular disease by pharmacists. <i>Canadian Pharmacists Journal</i> , 2015, 148, 21-28.	0.4	6
42	A review of the use of direct oral anticoagulant use in orthotopic heart transplantation recipients. <i>Transplantation Reviews</i> , 2018, 32, 151-156.	1.2	6
43	Association Between Hemoglobin A1c and Major Adverse Coronary Events in Patients with Diabetes Following Coronary Artery Bypass Surgery. <i>Pharmacotherapy</i> , 2020, 40, 116-124.	1.2	6
44	Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis. <i>Annals of Pharmacotherapy</i> , 2019, 53, 997-1004.	0.9	3
45	Comment: supratherapeutic response to ezetimibe administered with cyclosporine. <i>Annals of Pharmacotherapy</i> , 2005, 39, 2141-2141.	0.9	2
46	Maintenance of improved lipid levels following attendance at a cardiovascular risk reduction clinic: a 10-year experience. <i>Vascular Health and Risk Management</i> , 2008, Volume 4, 1127-1135.	1.0	2
47	Making Hospital Pharmacists Indispensable on the Healthcare Team: Revolution in Waiting. <i>Journal of Pharmacy Practice and Research</i> , 2009, 39, 256-257.	0.5	2
48	Proprotein convertase subtilisin/kexin type 9 inhibitors for reduction of cardiovascular events. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 747-754.	0.5	2
49	Macrolide Antibiotics and Calcineurin Inhibitors: Avoiding a Far too Common Drug Interaction in Transplant Patients. <i>Canadian Pharmacists Journal</i> , 2009, 142, 68-70.	0.4	1
50	The Art of Planning. <i>Canadian Journal of Hospital Pharmacy</i> , 2014, 67, 324.	0.1	1
51	A New Year's Time for Reconciliation. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, .	0.1	1
52	Comment: Should an LDL Cholesterol Target-Based Approach Be Readopted?. <i>Annals of Pharmacotherapy</i> , 2018, 52, 706-707.	0.9	1
53	The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?. <i>Canadian Journal of Cardiology</i> , 2019, 35, 558-563.	0.8	1
54	Lipid therapy: A new whiteboard video for patient education. <i>Canadian Pharmacists Journal</i> , 2021, 154, 175-178.	0.4	1

#	ARTICLE	IF	CITATIONS
55	The Canadian Consensus Working Group's Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. <i>Contemporary Cardiology</i> , 2020, , 137-150.	0.0	1
56	A new year-time for reconciliation. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, 96.	0.1	1
57	Gaps, Goals and Getting to Target: A Call to Action for Pharmacists!. <i>Canadian Pharmacists Journal</i> , 2008, 141, S6-S6.	0.4	0
58	Low-dose ASA Use for Primary Prevention of Cardiovascular Disease in Patients without Diabetes: When Should You Recommend it? A Case-Based Approach. <i>Canadian Pharmacists Journal</i> , 2011, 144, 278-286.e1.	0.4	0
59	Research Grants from the CSHP Research and Education Foundation. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 152.	0.1	0
60	Un changement de saison, un nouveau départ!. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, .	0.1	0
61	A Change of Seasons – A New Beginning!. <i>Canadian Journal of Hospital Pharmacy</i> , 2015, 68, 436.	0.1	0
62	New Antilipid Drugs: Do the Known Benefits Justify the Expense?. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 323-6.	0.1	0
63	Belonging to CSHP – An Investment in Your Future and That of Hospital Pharmacy!. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 180.	0.1	0
64	Faire partie de la SCPH – un investissement dans votre avenir et celui de la pharmacie hospitalière!. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, .	0.1	0
65	The Pursuit of Professional Practice Excellence and the Achievement of Peer Recognition. <i>Canadian Journal of Hospital Pharmacy</i> , 2017, 70, 92.	0.1	0
66	La recherche de l'excellence en pratique professionnelle et l'obtention de la reconnaissance des pairs. <i>Canadian Journal of Hospital Pharmacy</i> , 2017, 70, .	0.1	0
67	Le passé, le présent et un avenir très radieux. <i>Canadian Journal of Hospital Pharmacy</i> , 2017, 70, .	0.1	0
68	The Past, the Present, and a Very Bright Future. <i>Canadian Journal of Hospital Pharmacy</i> , 2017, 70, 328.	0.1	0
69	Remote Pharmacist Practice Model of Collaboration in Primary Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004801.	0.9	0
70	Comparison of Preventive Cardiovascular Pharmacotherapy in Surgical vs Percutaneous Coronary Revascularization. <i>CJC Open</i> , 2019, 1, 297-304.	0.7	0
71	Prescribing by Pharmacists and Collaborative Care: Are We Ready to Accept the Baton and Get in the Race?. <i>Canadian Journal of Hospital Pharmacy</i> , 2010, 63, 59.	0.1	0
72	Non-Immunosuppressant Medication Use in Heart Transplant Patients: A Guide for Pharmacists. <i>Pharmacology &amp; Pharmacy</i> , 2014, 05, 950-958.	0.2	0

#	ARTICLE	IF	CITATIONS
73	L'art de la planification. Canadian Journal of Hospital Pharmacy, 2014, 67, .	0.1	0
74	Une nouvelle année : l'heure est au bilan. Canadian Journal of Hospital Pharmacy, 2015, 68, 95.	0.1	0
75	Death to the Print Format" But Let Us Not Forget Our Past. Canadian Journal of Hospital Pharmacy, 2015, 68, 494.	0.1	0
76	Evaluation of the Management of Hyperlipidemia and Hypertension in an Outpatient Cardiac Transplant Clinic. Pharmacology & Pharmacy, 2016, 07, 71-80.	0.2	0
77	Omega-3 fatty acids for cardiovascular disease prevention: A practice tool for pharmacists. Canadian Pharmacists Journal, 2022, 155, 171516352210876.	0.4	0